Log in

LON:GDR - Genedrive Share Price, Forecast & News

GBX 19.50
-3.50 (-15.22 %)
(As of 03/29/2020 03:15 PM ET)
Today's Range
18.25
Now: GBX 19.50
25.18
50-Day Range
8.75
MA: GBX 9.67
29.50
52-Week Range
6.25
Now: GBX 19.50
28
Volume1.04 million shs
Average Volume9,606 shs
Market Capitalization£6.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. It operates through three divisions: Preclinical Research Services, Pharmacogenomic Services, and Diagnostics. The Preclinical Research Services division provides pre-clinical testing services in the areas of oncology, oncology supportive care, inflammatory bowel disease, leukaemia, gastrointestinal disease, inflammation, skin care and wound healing, and rheumatoid arthritis. The Pharmacogenomic Services division offers molecular measures of biological processes. The Diagnostics division is involved in commercializing the Genedrive point of need molecular testing platform. It serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is based in Manchester, the United Kingdom.
Read More
Genedrive logo

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-9890245

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£1.50 million
Cash FlowGBX 21.67 per share
Book ValueGBX (15.80) per share

Profitability

Miscellaneous

Employees72
Market Cap£6.80 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GDR News and Ratings via Email

Sign-up to receive the latest news and ratings for GDR and its competitors with MarketBeat's FREE daily newsletter.


Genedrive (LON:GDR) Frequently Asked Questions

How has Genedrive's stock been impacted by COVID-19 (Coronavirus)?

Genedrive's stock was trading at GBX 9 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GDR stock has increased by 116.7% and is now trading at GBX 19.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genedrive?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genedrive in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genedrive.

How were Genedrive's earnings last quarter?

Genedrive PLC (LON:GDR) announced its quarterly earnings results on Tuesday, February, 4th. The company reported ($8.90) EPS for the quarter. View Genedrive's earnings history.

Has Genedrive been receiving favorable news coverage?

Media coverage about GDR stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genedrive earned a news impact score of 2.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutGenedrive.

Who are some of Genedrive's key competitors?

What other stocks do shareholders of Genedrive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genedrive investors own include NVIDIA (NVDA), Allena Pharmaceuticals (ALNA), Chuy's (CHUY), Comtech Telecomm. (CMTL), Cisco Systems (CSCO), FormFactor (FORM), Hub Group (HUBG), Mondelez International (MDLZ), Methanex (MEOH) and Manitex International (MNTX).

Who are Genedrive's key executives?

Genedrive's management team includes the following people:
  • Mr. David Budd, CEO & Director (Age 51)
  • Mr. Matthew J. Fowler, CFO, Company Sec. & Director (Age 44)

What is Genedrive's stock symbol?

Genedrive trades on the London Stock Exchange (LON) under the ticker symbol "GDR."

How do I buy shares of Genedrive?

Shares of GDR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Genedrive's stock price today?

One share of GDR stock can currently be purchased for approximately GBX 19.50.

How big of a company is Genedrive?

Genedrive has a market capitalization of £6.80 million and generates £1.50 million in revenue each year. Genedrive employs 72 workers across the globe. View additional information about Genedrive.

What is Genedrive's official website?

The official website for Genedrive is http://www.genedriveplc.com/.

How can I contact Genedrive?

Genedrive's mailing address is 48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom. The company can be reached via phone at +44-161-9890245.


MarketBeat Community Rating for Genedrive (LON GDR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  233 (Thanks for Voting!)
Underperform Votes:  175 (Thanks for Voting!)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about Genedrive and other stocks. Vote "Outperform" if you believe GDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel